Skip to main content

AstraZeneca PLC

corporate_fare Company Profile

AstraZeneca PLC

AZN·NYSE·Life Sciences·CIK 0000901832

AstraZeneca PLC is a public limited company based in the United Kingdom. The company was formed in 1993 when the pharmaceutical, agrochemical, and specialty chemical businesses of Imperial Chemical Industries PLC were separated. Initially named Zeneca Group PLC, it changed its name to AstraZeneca PLC on April 6, 1999. In 1999, the company sold its specialty chemical business and merged with Astra of Sweden. In 2000, it separated its agrochemical business and merged it with Novartis's similar business to create Syngenta AG. The company expanded its operations in 2007 by acquiring MedImmune, a biologics and vaccines business located in the United States. In 2021, AstraZeneca further grew by acquiring Alexion, a rare disease business also based in the United States. In connection with the 1999 merger with Astra, the company's share capital was redenominated in US dollars. On April 6, 1999, Zeneca shares were cancelled and new US dollar-denominated shares were issued, credited as fully paid, on a one-for-one basis. The company also issued 50,000 Redeemable Preference Shares for cash, at par, at the same time.

AstraZeneca PLC (NYSE:AZN) is a publicly traded company in the Life Sciences sector. Wiseek monitors AZN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • AstraZeneca Sets AGM Agenda: Proposes New Auditor, Major Share Allotment & Buyback Authorizations
  • AstraZeneca Finalizes $2.0 Billion Senior Notes Offering Across Three Tranches
  • AstraZeneca Reports Strong 2025 Financial Growth and Robust Pipeline Progress in Annual Report
  • AstraZeneca Reports Robust FY2025 Results, Strategic Pipeline Progress, and Global Expansion
  • AstraZeneca's Calquence Combo Receives US FDA Approval for 1st-Line CLL Treatment

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$58.74B
Net Income
$10.23B
Diluted EPS
$6.54
Op. Cash Flow
$14.57B
Free Cash Flow
$11.77B
Gross Profit
$48.11B
Operating Income
$13.74B
Cash & Equivalents
$1.33B
Total Debt
$24.71B
Debt / Equity
0.51×
Net Margin
17.4%
Source: 20-F · filed 2026-02-24 · accession 0001104659-26-019130

Insider Transactions

AZN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$178.75
52-week range · as of 2026-05-29 $131.03 – $212.71
Market cap
$277.22B
Volume
2.4M (1.2× avg)
3-mo avg 1.9M
Live data · 2026-06-14 03:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AZN - Filings & News (Page 2)

AZN
Mar 10, 2026, 7:37 AM EDT
Filing Type: 6-K
Importance Score:
7
AstraZeneca Sets AGM Agenda: Proposes New Auditor, Major Share Allotment & Buyback Authorizations
Price at Filing: $197.71
Real-time Price: $178.75 info
Change: -$18.96 (-10%) info
Market Cap: $277.217B info
Sentiment: Neutral
View Wiseek Article
AZN
Feb 25, 2026, 6:35 PM EST
Filing Type: FWP
Importance Score:
7
AstraZeneca Finalizes $2.0 Billion Senior Notes Offering Across Three Tranches
Price at Filing: $206.87
Real-time Price: $178.75 info
Change: -$28.12 (-14%) info
Market Cap: $277.217B info
Sentiment: Neutral
View Wiseek Article
AZN
Feb 24, 2026, 4:17 PM EST
Filing Type: 20-F
Importance Score:
9
AstraZeneca Reports Strong 2025 Financial Growth and Robust Pipeline Progress in Annual Report
Price at Filing: $206.61
Real-time Price: $178.75 info
Change: -$27.86 (-13%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Feb 24, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
9
AstraZeneca Reports Robust FY2025 Results, Strategic Pipeline Progress, and Global Expansion
Price at Filing: $206.61
Real-time Price: $178.75 info
Change: -$27.86 (-13%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Feb 20, 2026, 6:57 AM EST
Filing Type: 6-K
Importance Score:
8
AstraZeneca's Calquence Combo Receives US FDA Approval for 1st-Line CLL Treatment
Price at Filing: $206.64
Real-time Price: $178.75 info
Change: -$27.89 (-13%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Feb 10, 2026, 11:55 AM EST
Filing Type: 6-K
Importance Score:
8
AstraZeneca Reports Strong FY25 Results, Positive 2026 Guidance, and Key Pipeline Progress
Price at Filing: $193.21
Real-time Price: $178.75 info
Change: -$14.46 (-7%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Feb 02, 2026, 7:51 AM EST
Filing Type: 6-K
Importance Score:
8
EU Committee Recommends AstraZeneca's Imfinzi for Early Gastric & GEJ Cancers
Price at Filing: $92.83
Real-time Price: $178.75 info
Change: +$85.92 (+93%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Feb 02, 2026, 7:25 AM EST
Filing Type: 6-K
Importance Score:
8
AstraZeneca Begins Trading Ordinary Shares on NYSE, Harmonizing Global Listings
Price at Filing: $92.83
Real-time Price: $178.75 info
Change: +$85.92 (+93%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Jan 30, 2026, 6:19 AM EST
Filing Type: 6-K
Importance Score:
8
AstraZeneca Expands Obesity & Diabetes Pipeline with $1.2B Upfront CSPC Collaboration
Price at Filing: $92.78
Real-time Price: $178.75 info
Change: +$85.97 (+93%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article
AZN
Jan 29, 2026, 8:08 AM EST
Filing Type: 6-K
Importance Score:
8
AstraZeneca Commits $15 Billion to Expand China R&D and Manufacturing Through 2030
Price at Filing: $93.05
Real-time Price: $178.75 info
Change: +$85.70 (+92%) info
Market Cap: $277.217B info
Sentiment: Positive
View Wiseek Article